PMID- 21934215
OWN - NLM
STAT- MEDLINE
DCOM- 20120119
LR  - 20191210
IS  - 0974-5130 (Electronic)
IS  - 0377-4929 (Linking)
VI  - 54
IP  - 3
DP  - 2011 Jul-Sep
TI  - Assessment of HER2/Neu status by fluorescence in situ hybridization in 
      immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant 
      signal patterns: a study at a tertiary cancer center.
PG  - 532-8
LID - 10.4103/0377-4929.85087 [doi]
AB  - INTRODUCTION: HER-2/neu status determines the eligibility for targeted therapy 
      with trastuzumab in breast carcinoma. Evaluation for HER-2/neu protein expression 
      by immunohistochemistry (IHC) and gene amplification by fluorescence in situ 
      hybridization (FISH) has become the gold standard. AIMS: Since data on HER-2/neu 
      assessment by IHC and FISH and studies regarding concordance between the results 
      of the two techniques are limited, especially from India, we sought to study 
      HER-2 gene amplification status by FISH in equivocal (2+) cases by IHC and also 
      study aberrant signal patterns. SETTINGS AND DESIGN: Mastectomies and breast core 
      biopsies, equivocal for HER-2/neu protein expression, were analyzed for HER-2 
      amplification by FISH. MATERIALS AND METHODS: IHC (DAKO) and FISH (PathVysion 
      dual-probe system) tests were performed on 68 of 112 (after exclusion) 10% 
      neutral buffered formalin (NBF)-fixed paraffin-embedded tissues and evaluated 
      according to American Society of Clinical Oncology ASCO guidelines. STATISTICAL 
      ANALYSIS USED: Chi-square (chi2) test and the two-tailed P value were applied using 
      Graphpad Quickcels software, version 2006. RESULTS: It was found that 73.5% of 
      the IHC 2+ patients were negative for HER-2/neu amplification, 25% were positive 
      (ratios ranging from 2.3 to 5.6) and 1 patient was equivocal (2.2). Retesting 
      FISH HER-2 equivocal case on another tumor block by IHC demonstrated HER-2 
      overexpression of protein 3+, thus resolving the equivocal status. Polysomy and 
      HER-2 genetic heterogeneity were seen frequently. CONCLUSIONS: The findings 
      reiterate that IHC HER-2 equivocal cases are a heterogeneous group and need FISH 
      for further categorization. Low concurrence (25%) rate between both IHC and FISH 
      results in the equivocal scenario can be attributed to tumors with polysomy 17 
      and HER-2/neu genetic heterogeneity.
FAU - Murthy, Sudha S
AU  - Murthy SS
AD  - Department of Laboratory Medicine (Pathology and Molecular Diagnostics), 
      Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, 
      India. sudha.s@induscancer.com
FAU - Sandhya, D G
AU  - Sandhya DG
FAU - Ahmed, Faiq
AU  - Ahmed F
FAU - Goud, K Iravathy
AU  - Goud KI
FAU - Dayal, Monal
AU  - Dayal M
FAU - Suseela, K
AU  - Suseela K
FAU - Rajappa, Senthil J
AU  - Rajappa SJ
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - India
TA  - Indian J Pathol Microbiol
JT  - Indian journal of pathology & microbiology
JID - 7605904
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy
MH  - Breast/pathology
MH  - Breast Neoplasms/*diagnosis/pathology
MH  - Carcinoma, Ductal/*diagnosis/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - India
MH  - Mastectomy
MH  - Microscopy
MH  - Middle Aged
MH  - Pathology, Molecular/*methods
MH  - Receptor, ErbB-2/*genetics
EDAT- 2011/09/22 06:00
MHDA- 2012/01/20 06:00
CRDT- 2011/09/22 06:00
PHST- 2011/09/22 06:00 [entrez]
PHST- 2011/09/22 06:00 [pubmed]
PHST- 2012/01/20 06:00 [medline]
AID - IndianJPatholMicrobiol_2011_54_3_532_85087 [pii]
AID - 10.4103/0377-4929.85087 [doi]
PST - ppublish
SO  - Indian J Pathol Microbiol. 2011 Jul-Sep;54(3):532-8. doi: 
      10.4103/0377-4929.85087.